浙江拱东医疗器械股份有限公司 董事、高级管理人员离职管理制度 第一章 总则 第一条 为规范浙江拱东医疗器械股份有限公司（以下简称"公司"）董事、 高级管理人员离职程序，确保公司治理结构的稳定性和连续性，维护公司及股 东的合法权益，公司根据《中华人民共和国公司法》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等法律、法规、规范性文件及《浙江拱东 医疗器械股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合公 司实际情况，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员因任期 届满、辞任、被解除职务等离职情形。 第二章 离职情形与生效条件 第三条 董事、高级管理人员候选人的任职资格应当符合法律法规、中国证 券监督管理委员会（以下简称"中国证监会"）和上海证券交易所业务规则及 《公司章程》等公司制度的规定。存在下列情形之一的，不得担任公司董事或 者高级管理人员： （一）无民事行为能力或者限制民事行为能力； 第四条 董事、高级管理人员辞任应向公司提交书面辞职报告。除本条第二 款规定的情形外，董事、高级管理人员辞任的，自公司收到辞任报告之日生效。 出现下列规定情形的， ...

Company Overview - Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, development, production, and sales of disposable medical consumables [1] - The main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - For Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - The net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The gross profit margin stood at 32.40% [1] Market Position - As of August 22, the company's stock closed at 20.45 yuan, down 1.06%, with a rolling PE ratio of 29.29 times [1] - The total market capitalization is 4.509 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Gongdong Medical at the 58th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,909, up by 735 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Company Overview - Company name: Zhejiang Gongdong Medical Technology Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - For Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's current stock price is 20.23 yuan, with a PE ratio of 28.98 times [1] - The total market capitalization is 4.461 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 55.76 times and a median of 39.14 times, the company ranks 57th [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 8,909, an increase of 735 from the previous count [1] - The average market value held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

8月12日，拱东医疗今日收盘21.06元，上涨1.10%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到30.17倍，创35天以来新低，总市值46.44亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均57.51倍，行业中值41.25倍，拱东医疗排 名第58位。 股东方面，截至2025年3月31日，拱东医疗股东户数8909户，较上次增加735户，户均持股市值35.28万 元，户均持股数量2.76万股。 浙江拱东医疗器械股份有限公司的主营业务是一次性医用耗材的研发、生产和销售。公司的主要产品是 医疗检测类、血液收集类、采集类、医用护理类、药品包装类、其他。 最新一期业绩显示，2025年一季报，公司实现营业收入2.64亿元，同比-2.74%；净利润2741.25万元，同 比-39.23%，销售毛利率32.40%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13拱东医疗30.1727.062.6846.44亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Gongdong Medical, which closed at 20.96 yuan, up 3.76%, with a rolling PE ratio of 30.02, marking a new low in 33 days, and a total market capitalization of 4.622 billion yuan [1][2] - Gongdong Medical's PE ratio is significantly lower than the industry average of 55.70 and the industry median of 39.08, ranking 58th in the medical device sector [1][2] - As of March 31, 2025, Gongdong Medical had 8,909 shareholders, an increase of 735 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Gongdong Medical specializes in the research, production, and sales of disposable medical consumables, with key products including medical testing, blood collection, collection, medical care, and drug packaging [1] - The latest quarterly report for Q1 2025 shows Gongdong Medical achieved revenue of 264 million yuan, a year-on-year decrease of 2.74%, and a net profit of 27.41 million yuan, down 39.23%, with a gross profit margin of 32.40% [1]

证券时报·数据宝统计，截至今日下午13:59，上证综指3639.35点，收于年线之上，涨跌幅为0.15%，A 股总成交额为15144.52亿元。到目前为止，今日有19只A股价格突破了年线，其中乖离率较大的个股有 富满微、斯达半导、ST立方等，乖离率分别为19.00%、8.64%、8.08%；中国海油、拱东医疗、浙江新 能等个股乖离率较小，刚刚站上年线。 8月7日突破年线个股乖离率排名 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 300671 | 富满微 | 20.00 | 12.24 | 33.78 | 40.20 | 19.00 | | 603290 | 斯达半 导 | 10.00 | 8.26 | 86.71 | 94.20 | 8.64 | | 300344 | ST立方 | 14.26 | 11.36 | 5.86 | 6.33 | 8.08 | | 300613 | 富瀚微 | 7 ...

7月31日突破年线个股乖离率排名 证券时报·数据宝统计，截至今日上午10:29，上证综指3583.25点，收于年线之上，涨跌幅为-0.90%，A 股总成交额为8429.51亿元。到目前为止，今日有12只A股价格突破了年线，其中乖离率较大的个股有珠 海中富、振江股份、紫光股份等，乖离率分别为4.59%、2.51%、1.98%；亚华电子、拱东医疗、昆仑万 维等个股乖离率较小，刚刚站上年线。 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 000659 | 珠海中 | 5.09 | 4.36 | 2.76 | 2.89 | 4.59 | | | 富 | | | | | | | 603507 | 振江股 | 4.38 | 8.98 | 23.94 | 24.54 | 2.51 | | | 份 | | | | | | | 000938 | 紫光股 | 2.06 | 1.81 | 24.77 | 25.26 ...

Market Overview - The Shanghai Composite Index closed at 3609.71 points, above the annual line, with a change of 0.33% [1] - The total trading volume of A-shares reached 18293.09 billion yuan [1] Stocks Breaking Annual Line - A total of 26 A-shares have surpassed the annual line today, with notable stocks including Sinochem International, Dier Laser, and Blue Arrow Electronics, showing divergence rates of 8.45%, 4.04%, and 2.76% respectively [1] - Stocks with smaller divergence rates that just crossed the annual line include Weimob Communication, Huaibei Mining, and Tongxiang Technology [1] Top Stocks by Divergence Rate - The top three stocks with the highest divergence rates are: - Sinochem International: 10.10% increase, latest price 4.25 yuan, divergence rate 8.45% [1] - Dier Laser: 4.31% increase, latest price 60.98 yuan, divergence rate 4.04% [1] - Blue Arrow Electronics: 2.94% increase, latest price 21.68 yuan, divergence rate 2.76% [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Guangfeng Technology: 3.97% increase, latest price 15.72 yuan, divergence rate 2.62% [1] - Foster: 10.04% increase, latest price 14.69 yuan, divergence rate 2.44% [1] - I Love My Home: 2.56% increase, latest price 3.21 yuan, divergence rate 2.39% [1]

Core Viewpoint - Zhejiang Gongdong Medical Instrument Co., Ltd. has completed the registration change and obtained a new business license, reflecting an increase in registered capital from 157,578,415 yuan to 220,492,949 yuan, indicating a significant growth in the company's financial structure [1][2]. Group 1: Company Changes - The company held its 14th meeting of the third board of directors on April 21, 2025, and the annual shareholders' meeting on May 27, 2025, where the proposal to change the registered capital and amend the articles of association was approved [1]. - The total number of shares has increased from 157,578,415 shares to 220,492,949 shares following the capital change [1]. Group 2: Business License Information - The new business license issued by the Zhejiang Provincial Market Supervision Administration includes the updated registered capital of 220,492,949 yuan and confirms the company type as a listed other joint-stock company [1]. - The company was established on August 17, 2009, and is located at No. 10, Beiyuan Avenue, Huangyan District, Taizhou City, Zhejiang Province [1]. Group 3: Business Scope - The company is authorized to produce and operate Class II and Class III medical devices, as well as disposable medical supplies and food-grade plastic packaging containers [1]. - The general business activities include sales of Class I and Class II medical devices, production of protective equipment for medical personnel, and various technical services and consulting [1].

Summary of Key Points Core Viewpoint The articles outline the corporate governance structure, operational objectives, and shareholder rights of Zhejiang Gongdong Medical Technology Co., Ltd., emphasizing the company's commitment to high-quality medical products and services while adhering to legal regulations. Group 1: Company Overview - The company is established as a joint-stock limited company based on the original Zhejiang Gongdong Medical Technology Co., Ltd. and registered with the Zhejiang Provincial Market Supervision Administration [3] - The company was approved by the China Securities Regulatory Commission to issue 20 million shares of ordinary stock to the public on August 21, 2020, and was listed on the Shanghai Stock Exchange on September 16, 2020 [3][4] - The registered capital of the company is RMB 220,492,949 [4] Group 2: Business Objectives and Scope - The company's business objective is to adhere to the principle of "high quality, high efficiency, mutual development, and common prosperity," striving for excellence in providing outstanding products and services to the medical industry [5] - The company's operational scope includes the production and sale of various medical devices, including Class II and Class III medical devices, as well as disposable medical supplies and food-grade plastic packaging [5] Group 3: Shareholder Rights and Governance - The company's articles of association serve as a legally binding document that regulates the rights and obligations of the company, shareholders, directors, supervisors, and senior management [5] - Shareholders have the right to receive dividends, participate in shareholder meetings, supervise the company's operations, and request information [15] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for proposing and voting on resolutions [19][29] Group 4: Board of Directors and Management - The board of directors is responsible for the company's strategic decisions, including the election and remuneration of directors and supervisors [18] - The company has established a management structure that includes a general manager and other senior management personnel, who are accountable to the board of directors [5][18] Group 5: Financial and Audit Regulations - The company is required to maintain a financial accounting system, conduct internal audits, and appoint external auditors [5] - The articles specify the procedures for capital increases, reductions, and share repurchases, ensuring compliance with relevant laws and regulations [10][11]